The Homo sapiens charged multivesicular body protein 5 (CHMP5) is a member of the multivesicular body, which serves as an anti-apoptotic protein and is thought to participate in leukemogenesis. In this study, a short-hairpin RNAbased RNA interference approach was used to inhibit the expression of CHMP5 in the leukemic cell line U937. After CHMP5 was inhibited, antibody microarray and western blot analysis were used to study the changes in the programmed cell death (PCD) pathway. PCD can be classified into three types: apoptosis, necrosis, and autophagy. Results showed that caspase 3 was activated in CHMP5-deficient U937 cells, indicating that the apoptotic pathway was activated, although neither the intrinsic nor the extrinsic apoptotic pathways were activated. Our results also showed that the Granzyme B/Perforin apoptotic pathway was activated by CHMP5 silencing. Necrosis is activated by caspase-independent executioners. In this study, we showed that the apoptosis-inducing protein-mediated necrotic PCD pathway is activated after CHMP5 inhibition. It was found that autophagic PCD did not occur in CHMP5-deficient U937 cells. In conclusion, after CHMP5 inhibition, both Granzyme B/Perforin apoptotic pathway and apoptosis-inducing factor-mediated necrotic pathway were activated, while autophagic pathway was not activated.
Introduction
The multivesicular body (MVB) is a special type of late endosome and is a crucial intermediate in the internalization of nutrients, ligands, and receptors through the endolysosomal system. The MVB plays a crucial role in sorting membrane proteins destined for degradation or routing to the lysosome [1, 2] . These proteins, such as activated growth factors, hormones, and cytokine receptors are internalized into vesicles that form the MVB. The contents of the MVB are then transferred to lysosomes for degradation [3] [4] [5] . The Homo sapiens charged multivesicular body protein 5 gene (CHMP5; GenBank accession number: NM 016410), also known as PNAS-2, is a member of the CHMP family of coiled-coil protein genes. CHMP5 is a highly conserved protein, and its homologues can be found in organisms such as Caenorhabditis elegans, Arabidopsis thaliana, and yeast [4] . CHMP5 is a component of the endosomal sorting complex required for transport III (ESCRT-III). Through a coherent protein network, the ESCRT complexes 0, I, II, III, and associated proteins form a large MVB sorting complex on endosomal membranes [5] [6] [7] . ESCRT-III is involved in the degradation of surface receptor proteins, formation of endocytic multivesicular bodies, and down-regulation of several signaling pathways [6] . CHMP5 is responsible for the final conversion of late endosomal MVB to lysosomes and plays a critical role in the down-regulation of signaling pathways through receptor degradation [4] .
The CHMP5 gene is located on chromosome 9q13.3, whose 5 0 end is only 414 bp away from the opposing strands of the BAG-1 gene, suggesting that these two genes may be co-regulated at the transcriptional level [8] . BAG-1 is an anti-apoptotic protein that is also a multifunctional regulator of apoptosis, cell proliferation, transcription, and cell motility [9, 10] . This implies that CHMP5 may participate in functions modulated by BAG-1. Functional analyses of CHMP5 have been carried out in our lab using RNAi and protein overexpression strategies. We found that CHMP5 is an anti-apoptotic gene [11] , consistent with the findings of Shahmoradgoli et al. [12] . Moreover, we also found that CHMP5 was significantly increased in de novo or relapsed acute leukemia, indicating that it may participate in leukemogenesis [11, 12] .
Two main types of programmed cell death (PCD) have been well distinguished in the past decade: apoptosis and necrosis. Apoptosis, recurrently associated with the activation of caspases, was initially considered to be the only physiological and programmed form of cell death. However, it is now widely recognized that PCD can also occur in the complete absence of caspase activation. The existence of non-caspase PCD pathways was corroborated by the discovery of caspase-independent executioners, such as the mitochondrial protein apoptosis-inducing factor (AIF). Increasing evidence showed that AIF-mediated caspase-independent necrosis could be a highly orchestrated type of PCD [13, 14] . Upon activation of PCD, AIF is released from the mitochondria and translocated into the nucleus, inducing phosphatidylserine exposure, chromatin condensation, and DNA fragmentation [15, 16] . Phosphatidylserine exposure can be detected by annexin V. In our previous studies, we found that CHMP5 inhibition caused phosphatidylserine exposure increase and chromatin condensation [11] . This may indicate that CHMP5 inhibition may result in the activation of AIF-mediated caspase-independent necrosis.
Recently, autophagy, defined as type II PCD [17] , has also been determined to be a genetically programmed, regulated process by which cells undergo self-elimination. In some cellular settings, autophagy can serve as a cell survival pathway, suppressing apoptosis, and in other settings, it can lead to cell death [18] . Currently, there is clear evidence that efficient autophagic degradation requires functional MVB [19] . ESCRT-III has been implicated in the autophagic pathway and plays a role in the clearance of protein aggregates that characterize neurodegenerative disorders [20 -22] . Several interacting partners of CHMP5 in the ESCRT-III complex, such as CHMP2A, CHMP2B, CHMP4A, and CHMP6, are regulated by CHMP5 [12, 23] . Mutations in CHMP2B result in the inhibition of autophagic degradation in cells [22] . In this work, we also studied the relationship between CHMP5 and autophagy.
Antibody microarray is a high throughput technology used to screen for protein expression [24] . By multiplexing antibody-based methods through bead-based or microarraybased formats, multiple proteins may be assayed in parallel, with reduced consumption of samples and reagents. Many studies have shown the feasibility and promise of this technology [25, 26] . Here, we utilized antibody microarray technology to study protein alterations related to the apoptotic, necrotic, and autophagic pathways after CHMP5 was inhibited. We also attempted to elucidate the potential PCD pathway in CHMP5 deficiency.
Materials and Methods
Cell culture Human embryonic kidney cell line HEK293T and myelomonocytic leukemia cell line U937 were obtained from the Shanghai Institute of Hematology (Shanghai, China). The cells were cultured in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, and 100 mg/ ml streptomycin at 378C and 5% (v/v) CO 2 .
Construction of small interference RNA vectors and retroviral infection
The pSIREN-RetroQ plasmid was purchased from Clontech (Mountain View, USA). Retroviral Packaging Vectors pGag-Pol and pVSV-G were obtained from the Shanghai Institute of Hematology. Hairpin siRNA expression plasmid construction and transformation were performed according to our previous study [11] . The target sequence of CHMP5 for RNAi was 5 0 -CGTAGAGCAGAATCCATTGA-3 0 [11] . A retroviral supernatant was obtained by co-transfection of pGag-Pol, pVSV-G, and the retroviral expression vector containing the CHMP5 shRNA or shRNA control into HEK293T cells according to the manufacturer's protocol. U937 cells were infected with the viral supernatant, and the cells were then selected with 4 mg/ml puromycin for 2 weeks.
Real-time quantitative reverse transcription polymerase chain reaction Quantitative assessment of CHMP5 mRNA levels was determined by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) with an ABI 7900HT Sequence Detection System (Applied Biosystems, Foster City, USA). The human housekeeping gene RPII was used as an endogenous control. The following primers were used: CHMP5 sense 5 0 -CAGAAAGCCTTGCGA GTT-3 0 and CHMP5 antisense 5
and RPII antisense 5 0 -GTGCGGCTGCTTCCATAA-3 0 . The gene expression level was analyzed in triplicate, and U937 cDNA was used for calibration. Data were analyzed with Sequence Detection Systems (version 2.1) software (SDS 2.1).
Western blot analysis
Whole-cell extracts were prepared using RIPA buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 0.5% Triton X-100, 11.6 mM deoxycholic acid, and 0.1% SDS). Protein concentrations of the lysates were determined with the BCA protein assay kit (Thermo Scientific, Rockford, USA). Equal amounts of proteins were used for western blot analysis. The membranes were incubated overnight at 48C with the primary antibodies in TBS 0.1% Tween-20/5% milk, and then incubated with horseradish peroxidase-conjugated anti-mouse or anti-rabbit secondary antibodies for 1 h at room temperature, and analyzed using the ECL detection kit (Amersham, Freiburg, Germany).
The monoclonal anti-CHMP5 antibody was produced and kept in our laboratory. The polyclonal CHMP5 antibody was purchased from Abcam (Cambridge, UK). Granzyme B, microtubule-associated protein 1 light chain 3 (LC-3), and caspase 9 antibodies were purchased from Cell Signal Technology (Beverly, USA); AIF and caspase 3 antibodies were purchased from Epitomics (Burlingame, USA); the PARP antibody was purchased from Santa Cruz Biotechnology (Santa Cruz, USA); anti-caspase 8 antibody was purchased from BD Pharmingen (San Diego, USA); and the anti-nuclear factor-kappaB (NF-kB)/p65 antibody was purchased from Abcam.
Measurement of apoptosis and caspase 3 activity Cells were stained with annexin-allophycocyanin (APC)/ 7-amino-actinomycin (7-AAD; BD Pharmingen) and cell apoptosis was evaluated by flow cytometry. APC was optimized for FL-4 fluorescence on a flow cytometer, and 7-AAD fluorescence was detected in the far red range of the spectrum (650 nm long-pass filter) [11] . The results were calculated based on the percentages of both annexin V-APC þ /7-AAD 2 and annexin V-APC þ /7-AAD þ cells.
The NucView 488 caspase 3 assay kit for live cells was used (Biotium Inc., Hayward, USA) to detect caspase 3 activity changes after RNA interference.
Antibody microarray and apoptotic pathway analysis
The antibody microarray (Cat. No. TAA-001) was purchased from Lab Vision Corporation (Fremont, USA). The array contains 720 antibodies in triplicate, including a few housekeeping proteins as internal controls and multiple antibodies belonging to important biological processes such as apoptosis, necrosis, the mitotic cycle, and tumorigenesis. Proteins were extracted, labeled with biotin, and hybridized to the microarray. Slides were then scanned with Genepix 4000B (Axon, Union City, USA), with an excitation wavelength of 532 nm. The data were analyzed with Genepix Pro 6.0. Antibody microarrays were normalized according to the method of Hamelinck et al. [27] . Subsequently, the data were analyzed to define differentially regulated proteins. The antibody microarray results of important PCD-associated proteins were tested by western blot analysis.
Statistical analysis
All statistics were performed using SAS 6.12 software. Data are expressed as the mean + SD from three independent experiments. Statistical significance was determined using the t-test to compare groups of data. P values , 0.05 were considered statistically significant.
Results

Knock-down of CHMP5 by RNAi
The efficacy of CHMP5 shRNA on the knock-down of mRNA was confirmed by quantitative real-time PCR [ Fig. 1(A)] . The gene expression level in short-hairpin (sh)-CHMP5 group was down-regulated to 0.20 + 0.03 of that in the sh-Con group (P ¼ 0.0004). In addition, western blot analysis showed a significant reduction in CHMP5 protein abundance upon transfection of cells with CHMP5 shRNA compared with negative controls [ Fig. 1(B) ]. These results indicated that both the gene expression and protein expression of CHMP5 were down-regulated by RNA interference. Subsequently, we confirmed that the rate of apoptosis was increased after CHMP5 was inhibited [ Fig. 1(C) and Fig. S1 ]. The apoptotic rate was 4.99% + 0.66% in the control group; after CHMP5 was inhibited, the apoptotic rate increased to 18.14% + 0.96% (P ¼ 0.0003). The caspase 3 activity was also increased 2 folds (3.07 + 0.32, P ¼ 0.008) in the sh-CHMP5 group, relative to the sh-Con group [ Fig. 1(D) ].
Changes of protein expression measured by the antibody microarray
The antibody microarray analysis revealed that the inhibition of CHMP5 increased the levels of the PCD-related proteins such as AIF, Granzyme B, Perforin, NF-kB/p65 (Rel A), I-kappa-B kinase b, caspase 3, Bcl-2, Bcl-6, DcR1 (Decoy Receptor 1), Bcl-XL, CAD/DFF40 (DNA fragmentation factor 40), ICAD/DFF45 (DNA fragmentation factor 45), JAK-3, FLIP, JAK-3, SODD (silencer of death domain), and RAIDD .1.5 folds (Fig. 2) . Fas-ligand, Bcl 10, Bcl-X, and Bim (BOD) were down-regulated .1.5 folds. Protein expression levels of caspase 7 (Mch 3), caspase 8 (FLICE), caspase 9, BAG-1, Bak, Bax, CD95/ Fas, FADD (FAS-associated death domain-containing protein), I-FLICE/CASPER, TNF-alpha, and TRADD were altered ,1.5 folds (Fig. 2) .
Verification of the antibody microarray results by western blot analysis
The inhibition of CHMP5 by RNA interference resulted in increased expression of Granzyme B, AIF, NF-kB, Bcl-2, and cleaved (activated) caspase 3. The level of PARP, a substrate of activated caspase 3, was decreased and its cleavage was increased after CHMP5 was inhibited. But, western blot analysis revealed no obvious differences in caspase 8 and caspase 9 expression levels between the sh-Con and sh-CHMP5 groups (Fig. 3) . Microtubuleassociated protein 1 light chain 3 (LC3) localizes to the autophagosomal membranes after post-translational modifications. The C-terminal fragment of LC3 is cleaved immediately after synthesis to yield a cytosolic form called LC3-I. A subpopulation of LC3-I is further converted to an autophagosome-associating form called LC3-II. When autophagy is activated, conversion of LC3-I to LC3-II has been shown to be increased [28, 29] . We did not detect the conversion of LC3-I to LC3-II or any changes in LC3-I and LC3-II expression levels after CHMP5 was inhibited (Fig. 3) .
Discussion
PCD has been classified into three types. Type I PCD or apoptosis is critical for cellular self-destruction for a variety of processes, such as the development or the prevention of oncogenic transformation. Autophagy and necrosis are defined as type II and type III PCD, respectively [17] . Apoptosis is characterized by the activation of caspases, a family of cysteine proteases activated during apoptotic conditions. Necrosis is a non-caspase PCD pathway that is activated by caspase-independent executioners, such as AIF [13, 14] . In mammals, the conversion of microtubuleassociated protein 1 LC3 from LC3-I (free form) to LC3-II ( phosphatidylethanolamine-conjugated form) or the increase of LC3-II is a key step in autophagy [30] . Apoptosis is triggered by two major apoptosis-initiating pathways, designated as the intrinsic/mitochondria-mediated pathway and the extrinsic/receptor-mediated pathway. A common characteristic of most apoptotic processes is the activation of caspase cascades. In general, activation of procaspase 9 results in the initiation of the intrinsic pathway, whereas activation of procaspase 8 mediates the death receptor-regulated apoptosis, also known as the extrinsic pathway [31] . Activation of either pathway leads to the activation of the downstream caspase 3 and caspase 7.
Using gene microarray instead of antibody microarray, Shahmoradgoli et al. [12] found that CHMP5 deficiency Figure 1 CHMP5 expression after RNA interference After U937 cells were infected with the viral supernatant, the cells were selected with 4 mg/ml puromycin for 2 weeks. The expression of CHMP5 was obviously down-regulated after CHMP5 inhibition when assessed by real-time PCR (A) and western blot analysis (B). Cell apoptosis (C) and caspase 3 activity (D) were increased after CHMP5 inhibition when evaluated by flow cytometry.
induces apoptosis mainly via activation of the caspase 8 extrinsic cascade. Together with the results of caspase 3 activity assay, antibody microarray, and western blot analysis, we showed that caspase 3 is activated after CHMP5 silencing in U937 cells, indicating that the apoptotic pathway is activated. From the results of antibody microarray and western blot analysis, caspase 8 is not activated during CHMP5 silencing, and the inhibitors of the extrinsic apoptotic pathway such as DcR [32] , SODD [33] , FLIP [34, 35] , and NF-kB [36, 37] are increased. Moreover, the proapoptotic factors of the extrinsic apoptotic pathway such as Fas-ligand [38, 39] were decreased, which together indicate that the extrinsic apoptotic pathway is not activated. Additionally, caspase 9 is not activated, as demonstrated by both antibody microarray and western blot analysis. Consistently, levels of inhibitors of the intrinsic apoptotic pathway, such as Bcl-2 [40, 41] , were increased as confirmed by western blot analysis (Fig. 3) . Another inhibitor Western blot analysis of PCD-related proteins CHMP5 is normally expressed in the sh-Con group, while it is inhibited in the sh-CHMP5 group. We show that after CHMP5 is inhibited, AIF, Granzyme B (Gran B), activated caspase 3, NF-kB, and Bcl-2 proteins are increased, and PARP, a substrate of activated caspase 3, is cleaved. Alternatively, CHMP5 deficiency does not affect the activation of caspase 8 or caspase 9. Neither the conversion of LC3-I to LC3-II nor the increase of LC3-II is observed when CHMP5 is inhibited.
of the intrinsic apoptotic pathway Bcl-XL [40] was increased when detected by antibody microarray. Moreover, the proapoptotic factors of the intrinsic apoptotic pathway such as Bim [42, 43] were decreased, indicating that the intrinsic apoptotic pathway is also not activated. Shim et al. [4] have found that disrupting the mouse CHMP5 gene results in the deregulation of NF-kB. We show that CHMP5 inhibition results in the activation of NF-kB, indicating that NF-kB is actually modulated by CHMP5.
Apart from the two classical apoptotic pathways, there is at least one well-defined extrinsic pathway for induction of apoptosis, namely the Granzyme B/Perforin pathway [44, 45] . Granzyme B is a serine protease that specifically cleaves its substrates at Asp residues, similar to caspases. Granzymes are usually expressed by activated cytotoxic T lymphocytes and natural killer cells. Granzyme B may also be expressed by leukemic U937 cells [46, 47] . After Granzyme B binds its receptor, it is endocytosed but remains arrested in endocytic vesicles until it is released by Perforin [48, 49] . After Granzyme B is released to the cytoplasm, it directly cleaves and activates various procaspases, such as caspase 3, as well as other components of the apoptotic pathway and downstream caspase targets [48] . From our antibody microarray and western blot analyses, we demonstrate that Granzyme B protein expression is increased after CHMP5 inhibition. Furthermore, the antibody microarray shows that Perforin is increased during CHMP5 deficiency. These findings indicate that CHMP5 deficiency results in the activation of the Granzyme B/ Perforin pathway.
The apoptosis-inducing protein AIF is a Janus protein with redox activity in the mitochondria and proapoptotic function in the nucleus, and has previously been shown to function as a key factor of caspase-independent apoptosis [50] . Necrosis has often been viewed as an accidental and uncontrolled cell death process. Recently, AIF-induced apoptosis has been reported in caspase-independent necrosis [13] . In this study, we found that AIF protein expression was increased after CHMP5 was inhibited. These findings indicate that CHMP5 deficiency results in AIF-mediated caspase-independent necrosis.
Currently, clear evidence suggests that efficient autophagic degradation requires functional MVB [19, 22] . There is considerable evidence that indicates an important role for CHMP5 in autophagy. For example, CHMP2B and CHMP6 are regulated by CHMP5, and mutations in CHMP2B will result in the inhibition of autophagic degradation in cells [12, 22, 23] . CHMP5 inhibition results in an increase in Bcl-2, a proposed inhibitor of autophagy [51, 52] . We did not detect the conversion of LC3-I protein to LC3-II, nor did we detect an increase in LC3-II levels. These findings indicate that PCD by autophagy does not occur during CHMP5 deficiency.
In conclusion, we propose that two PCD pathways are activated after CHMP5 inhibition, the Granzyme B/Perforin apoptotic pathway and AIF-mediated caspase-independent necrosis pathway (Fig. 4) . The oncogene CHMP-5 is a potential target gene for leukemia therapy, and our findings are beneficial to better understand the role of this gene in the PCD. 
